Poliovirus type 3 antigen (formaldehyde inactivated) Completed Phase 4 Trials for Poliomyelitis / Diphtheria / Tetanus / Pertussis Prevention

clinicaltrials.gov IdentifierTitleDrugs
NCT01031303Immunogenicity and Safety of TETRAXIMâ„¢ Given as a Booster Dose at 4 to 6 Years of Age
NCT01437423Regulatory Post-Marketing Surveillance Study for TETRAXIMâ„¢
NCT01491087Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China